Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis
NCT02792218Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of ofatumumab in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: Annualized Relapse Rate at 2.5 years. Started Sep 2016; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02792218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792218.